Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2012
A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck.
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 113 citations in OpenAlex.
- A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin.Investigational new drugs · 2022Trial
- A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.Cancer medicine · 2021Trial
- Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2017Trial
- Use of the dual tyrosine kinase inhibitor lapatinib for the treatment of vulvovaginal squamous cell carcinoma in a dog.Journal of veterinary internal medicine · 2026Article
- Molecular imaging predicts trastuzumab-deruxtecan (T-DXd) response in head and neck cancer xenograft models.Molecular oncology · 2025Article
- Review
- Exploring the Therapeutic Implications of Co-Targeting the EGFR and Spindle Assembly Checkpoint Pathways in Oral Cancer.Pharmaceutics · 2024Review
- Targeted radionuclide therapy for head and neck squamous cell carcinoma: a review.Frontiers in oncology · 2024Review
- Current State and Future Directions of EGFR-Directed Therapy in Head and Neck Cancer.Current treatment options in oncology · 2023Review
- Review
- Review
- Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy.Therapeutic advances in medical oncology · 2021Review
- Nephrotoxicity in cancer treatment: An overview.World journal of clinical oncology · 2020Review
- Molecular biology of oral cavity squamous cell carcinoma.Oral oncology · 2020Article
- Article
- Targeted therapies for non-HPV-related head and neck cancer: challenges and opportunities in the context of predictive, preventive, and personalized medicine.The EPMA journal · 2019Review
- Current Prospects of Molecular Therapeutics in Head and Neck Squamous Cell Carcinoma.Pharmaceutical medicine · 2019Review
- Sustained complete response to erlotinib in squamous cell carcinoma of the head and neck: A case report.World journal of clinical cases · 2019Article
- Beyond EGFR Targeting in SCCHN: Angiogenesis, PI3K, and Other Molecular Targets.Frontiers in oncology · 2019Review
- An update: emerging drugs to treat squamous cell carcinomas of the head and neck.Expert opinion on emerging drugs · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 5 institutions in 1 country.
Funding
Abstract
purposeThis study sought to determine the efficacy and safety profile of lapatinib in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN). EXPERIMENTAL
designThis phase II multiinstitutional study enrolled patients with recurrent/metastatic SCCHN into two cohorts: those without (arm A) and those with (arm B) before exposure to an epidermal growth factor receptor (EGFR) inhibitor. All subjects were treated with lapatinib 1,500 mg daily. Primary endpoints were response rate (arm A) and progression-free survival (PFS; arm B). The biologic effects of lapatinib on tumor growth and survival pathways were assessed in paired tumor biopsies obtained before and after therapy.
resultsForty-five patients were enrolled, 27 in arm A and 18 in arm B. Diarrhea was the most frequent toxicity occurring in 49% of patients. Seven patients experienced related grade 3 toxicity (3 fatigue, 2 hyponatremia, 1 vomiting, and 1 diarrhea). In an intent-to-treat analysis, no complete or partial responses were observed, and stable disease was the best response observed in 41% of arm A (median duration, 50 days, range, 34-159) and 17% of arm B subjects (median, 163 days, range, 135-195). Median PFS was 52 days in both arms. Median OS was 288 (95% CI, 62-374) and 155 (95% CI, 75-242) days for arms A and B, respectively. Correlative analyses revealed an absence of EGFR inhibition in tumor tissue.
conclusionLapatinib as a single agent in recurrent/metastatic SCCHN, although well tolerated, appears to be inactive in either EGFR inhibitor naive or refractory subjects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.